Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis ( IPF ) include efficacy and safety results from TETON-1 and integrated results from TETON-1 and TETON-2 Results from the successful ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension ( PAH ) will be presented Additional presentations include an interim analysis from the TETON-PPF study of inhaled treprostinil in progressive pulmonary fibr

CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment options Fast Track designation reflects the significant unmet need and enables potential accelerated drug development WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) h

Research explored molecular and physical characteristics of IVIG products that may help inform scientific understanding relevant to clinical care and product selection TEANECK, N.J.--(BUSINESS WIRE)--GC Biopharma USA, Inc., a leader in plasma-derived products, announced today the presentation of new data at the 2026 Clinical Immunology Society (CIS) Annual Meeting in New Orleans, Louisiana. GC Biopharma’s presentations at CIS included two company-authored posters, one on molecular size distribut

Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers MENLO PARK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the publication of a preprint describing the first major study from the HiFi Solves Sub-fertility Consortium in Asia Pacific. The study highlights how HiFi whole genome sequencing coul

iStock, claudenakagawa The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head Vinay Prasad highlights the severe turnover rates at the highest rungs of leadership at the health department. The reported termination of FDA Commissioner Marty Makary could come as a double-edged sword for biopharma, experts say. On one hand, new agency leadership could restore some degree of predictability and trustworthiness to the regulator; on

Conference Posters and Presentations at ASGCT Showcase Utility of Countable PCR in Single Molecule Quantification for Cell and Gene Therapy Applications Proof-of-Concept Assay Services Now Available; Count What Counts Grant Program Will Provide Pilot Study to Selected Cell and Gene Therapy Researcher PALO ALTO, Calif.--(BUSINESS WIRE)-- #ASGCT2026 --Countable Labs, the developer of Countable PCR, the leading PCR innovation transforming how science measures biology, announced specialized assay se

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceedin

Therapeutic expression with durability past 6 months modeling hemophilia B treatment in non-human primate model Safe and redosable expression of DNA into the liver of pig and non-human primate models. Non-viral delivery and expression into genetic pig models of tyrosinemia and phenylketonuria showing ability to ameliorate relevant biomarkers. CAMBRIDGE, Mass. , May 11, 2026 /PRNewswire/ -- HydroGene Therapeutics is a biotechnology company creating accessible gene therapies for all liver dise

SUNRISE, Fla. , May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-strength Trelegy ® Ellipta ®1 (200 mcg/62.5 mcg/25 mcg) product, has been accepted for filing by the U.S. Food and Drug Administration (FDA

GE HealthCare to showcase next-gen technologies including helium-free 1.5T MR, advanced 3T scanner and state-of-the-art AI-powered workflow at ISMRM 2026 Advanced MR research tools help simplify collaboration and speed development, empowering researchers to push boundaries CHICAGO--(BUSINESS WIRE)--As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (Nasdaq: GEHC) today announced adva